Effective Date:

Monday, December 05, 2022

Test Updates

Modified
Test 8054B was removed

In our continuing effort to provide you with the highest quality toxicology laboratory services available, we have compiled important changes regarding a number of tests we perform. Listed below are the types of changes that may be included in this notification, effective Monday, December 05, 2022

Test Changes - Tests that have had changes to the method/ CPT code, units of measurement, scope of analysis, reference comments, or specimen requirements.

Discontinued Tests - Tests being discontinued with alternate testing suggestions.

Please use this information to update your computer systems/records. These changes are important to ensure standardization of our mutual laboratory databases.

If you have any questions about the information contained in this notification, please call our Client Support Department at (866) 522-2206. Thank you for your continued support of NMS Labs and your assistance in implementing these changes.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. NMS Labs does not assume responsibility for billing errors due to reliance on the CPT Codes listed in this document.

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
0650B	Biperiden, Blood								•
0650SP	Biperiden, Serum/Plasma								•
1063B	Chlorcyclizine, Blood								•
1266B	Clemastine, Blood								•
1266SP	Clemastine, Serum/Plasma								•
2532B	Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood					•		•	
2532SP	Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma					•		•	
2531B	Leflunomide as Metabolite (Therapeutic Drug Monitoring), Blood							•	
2531SP	Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma							•	
9203U	Methapyrilene Screen, Urine								•
2840SP	Methapyrilene, Serum/Plasma								•
3012B	Methotrimeprazine, Blood								•
3012SP	Methotrimeprazine, Serum/Plasma								•
4017B	Prilocaine, Blood								•
4017SP	Prilocaine, Serum/Plasma								•
9251B	Pyrilamine Screen, Blood								•
9251SP	Pyrilamine Screen, Serum/Plasma								•
4040B	Pyrilamine, Blood								•
4040SP	Pyrilamine, Serum/Plasma								•
4040U	Pyrilamine, Urine								•
4367B	Teriflunomide (Pre-Pregnancy Monitoring), Blood					•		•	
4367SP	Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma					•		•	
4366B	Teriflunomide (Therapeutic Drug Monitoring), Blood							•	
4366SP	Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma							•	
4378SP	Thenyldiamine, Serum/Plasma								•
4481B	Tiletamine, Blood								•
4481SP	Tiletamine, Serum/Plasma								•
9278U	Tocainide Screen, Urine								•
4488SP	Tocainide, Serum/Plasma								•
8691B	Trifluprom azine, Blood								•
4875B	Zolazepam, Blood								•

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Effective Date:

Monday, December 05, 2022

Test Updates

Test	Test Name	Test Name	Method / CPT Code	Specimen Req.	Stability	Scope	Units	Reference Comments	Discontinue
4875SP	Zolazepam, Serum/Plasma								•
4875U	Zolazepam, Urine								•

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Test Changes

2532B Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Blood

Summary of Changes: Scope of Analysis was changed.
Teriflunomide (Pre-Pregnancy) was added.
Reference Comment was changed.
Teriflunomide was removed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80193): Teriflunomide (Pre-Pregnancy)

Analyte Name	Units	Reference Comment
Teriflunomide (Pre-Pregnancy)	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The blood to plasma ratio is 0.5 to 0.7. The drug carries a black box warning for hepatotoxicity and pregnancy.

2532SP Leflunomide as Metabolite (Pre-Pregnancy Monitoring), Serum/Plasma

Summary of Changes: Scope of Analysis was changed.
Teriflunomide (Pre-Pregnancy) was added.
Reference Comment was changed.
Teriflunomide was removed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80193): Teriflunomide (Pre-Pregnancy)

Analyte Name	Units	Reference Comment
Teriflunomide (Pre-Pregnancy)	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
		of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The drug carries a black box warning for hepatotoxicity and pregnancy.

2531B Leflunomide as Metabolite (Therapeutic Drug Monitoring), Blood

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80193): Teriflunomide
Method (CPT Code)

Analyte Name	Units	Reference Comment
Teriflunomide	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The blood to plasma ratio is 0.5 to 0.7. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.

2531SP Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma

Test Updates

Test Changes

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80193): Teriflunomide
Method (CPT Code)

Analyte Name	Units	Reference Comment
Teriflunomide	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.

4367B Teriflunomide (Pre-Pregnancy Monitoring), Blood

Summary of Changes: Scope of Analysis was changed.
Teriflunomide (Pre-Pregnancy) was added.
Reference Comment was changed.
Teriflunomide was removed.

Scope of Analysis: LC-MS/MS (80375): Teriflunomide (Pre-Pregnancy)
Method (CPT Code)

Analyte Name	Units	Reference Comment
Teriflunomide (Pre-Pregnancy)	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
		concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The blood to plasma ratio is 0.5 to 0.7. The drug carries a black box warning for hepatotoxicity and pregnancy.

4367SP Teriflunomide (Pre-Pregnancy Monitoring), Serum/Plasma

Summary of Changes: Scope of Analysis was changed.
Teriflunomide (Pre-Pregnancy) was added.
Reference Comment was changed.
Teriflunomide was removed.

Scope of Analysis: Method (CPT Code): LC-MS/MS (80375): Teriflunomide (Pre-Pregnancy)

Analyte Name	Units	Reference Comment
Teriflunomide (Pre-Pregnancy)	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The drug carries a black box warning for hepatotoxicity and pregnancy.

4366B Teriflunomide (Therapeutic Drug Monitoring), Blood

Summary of Changes: Reference Comment was changed.

Test Updates

Test Changes

Scope of Analysis: LC-MS/MS (80375): Teriflunomide
Method (CPT Code)

Analyte Name	Units	Reference Comment
Teriflunomide	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL. Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. The blood to plasma ratio is 0.5 to 0.7. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.

4366SP Teriflunomide (Therapeutic Drug Monitoring), Serum/Plasma

Summary of Changes: Reference Comment was changed.

Scope of Analysis: LC-MS/MS (80375): Teriflunomide
Method (CPT Code)

Analyte Name	Units	Reference Comment
Teriflunomide	ng/mL	Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis. Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.

Test Updates

Test Changes

Analyte Name	Units	Reference Comment
		Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com

Test Updates

Discontinued Tests

Test	Test Name	Alternative Test
0650B	Biperiden, Blood	No Alternate Tests Available
0650SP	Biperiden, Serum/Plasma	No Alternate Tests Available
1063B	Chlorcyclizine, Blood	No Alternate Tests Available
1266B	Clemastine, Blood	No Alternate Tests Available
1266SP	Clemastine, Serum/Plasma	No Alternate Tests Available
9203U	Methapyrilene Screen, Urine	No Alternate Tests Available
2840SP	Methapyrilene, Serum/Plasma	No Alternate Tests Available
3012B	Methotrimeprazine, Blood	No Alternate Tests Available
3012SP	Methotrimeprazine, Serum/Plasma	No Alternate Tests Available
4017B	Prilocaine, Blood	No Alternate Tests Available
4017SP	Prilocaine, Serum/Plasma	No Alternate Tests Available
9251B	Pyrilamine Screen, Blood	No Alternate Tests Available
9251SP	Pyrilamine Screen, Serum/Plasma	No Alternate Tests Available
4040B	Pyrilamine, Blood	No Alternate Tests Available
4040SP	Pyrilamine, Serum/Plasma	No Alternate Tests Available
4040U	Pyrilamine, Urine	No Alternate Tests Available
4378SP	Thenyldiamine, Serum/Plasma	No Alternate Tests Available
4481B	Tiletamine, Blood	No Alternate Tests Available
4481SP	Tiletamine, Serum/Plasma	No Alternate Tests Available
9278U	Tocainide Screen, Urine	No Alternate Tests Available
4488SP	Tocainide, Serum/Plasma	No Alternate Tests Available
8691B	Triflupromazine, Blood	No Alternate Tests Available
4875B	Zolazepam, Blood	No Alternate Tests Available
4875SP	Zolazepam, Serum/Plasma	No Alternate Tests Available
4875U	Zolazepam, Urine	No Alternate Tests Available

NMS Labs
200 Welsh Rd.
Horsham, PA 19044-2208
nms@nmslabs.com